IMMU Stock Overview
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Mendus AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr0.45 |
52 Week High | kr1.67 |
52 Week Low | kr0.30 |
Beta | 0.98 |
1 Month Change | -8.26% |
3 Month Change | -2.49% |
1 Year Change | -70.00% |
3 Year Change | -91.62% |
5 Year Change | -94.30% |
Change since IPO | -94.71% |
Recent News & Updates
Recent updates
We're Keeping An Eye On Mendus' (STO:IMMU) Cash Burn Rate
Feb 20Mendus (STO:IMMU) Is Making Moderate Use Of Debt
Mar 28Is Mendus (STO:IMMU) Using Debt Sensibly?
Dec 01Is Mendus (STO:IMMU) Using Debt Sensibly?
Aug 10Health Check: How Prudently Does Immunicum (STO:IMMU) Use Debt?
May 10Is Immunicum (STO:IMMU) Using Too Much Debt?
Jan 31Shareholder Returns
IMMU | SE Biotechs | SE Market | |
---|---|---|---|
7D | -3.1% | 2.3% | 2.8% |
1Y | -70.0% | 0.2% | 13.6% |
Return vs Industry: IMMU underperformed the Swedish Biotechs industry which returned 3.4% over the past year.
Return vs Market: IMMU underperformed the Swedish Market which returned 14.7% over the past year.
Price Volatility
IMMU volatility | |
---|---|
IMMU Average Weekly Movement | 6.6% |
Biotechs Industry Average Movement | 9.6% |
Market Average Movement | 6.2% |
10% most volatile stocks in SE Market | 12.8% |
10% least volatile stocks in SE Market | 3.6% |
Stable Share Price: IMMU has not had significant price volatility in the past 3 months.
Volatility Over Time: IMMU's weekly volatility has decreased from 15% to 7% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2002 | 30 | Erik Manting | www.mendus.com |
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors. Its lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase II CADENCE clinical trial to treat AML; and Phase I ALISON clinical trial for the treatment of ovarian cancers. The company also develops ilixadencel, which completed Phase I clinical trial for the treatment of soft tissue sarcomas; and an NK cell program, which is in a preclinical study for NK cell-based therapies.
Mendus AB (publ) Fundamentals Summary
IMMU fundamental statistics | |
---|---|
Market cap | kr453.24m |
Earnings (TTM) | -kr101.62m |
Revenue (TTM) | kr28.49m |
15.9x
P/S Ratio-4.5x
P/E RatioIs IMMU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
IMMU income statement (TTM) | |
---|---|
Revenue | kr28.49m |
Cost of Revenue | kr0 |
Gross Profit | kr28.49m |
Other Expenses | kr130.11m |
Earnings | -kr101.62m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 17, 2024
Earnings per share (EPS) | -0.10 |
Gross Margin | 100.00% |
Net Profit Margin | -356.72% |
Debt/Equity Ratio | 0.1% |
How did IMMU perform over the long term?
See historical performance and comparison